Clinical Trial

A Safety and Pharmacokinetics Study of TL-003 in Healthy Adults and Open-label Assessments in Participants With Ulcerative Colitis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate safety, tolerability, pharmacokinetics (PK)), pharmacodynamics (PD) and immunogenicity of single and multiple ascending dose of TL-003 in healthy adult participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-06.
Trial Details
NCT Number NCT07526519
Lead Sponsor TrueLab Biopharmaceutical Co., Ltd
Collaborators: SAPRO Consulting Pty Ltd
Conditions Healthy Volunteer
Enrollment 48 participants
Start Date 2026-04-08
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-15